HARVARD BIOSCIENCE INC SEC Filing Summary

HARVARD BIOSCIENCE INC. Finalizes 1-for-10 Reverse Stock Split

Harvard Bioscience Inc. (NASDAQ: HBIO), a company that develops tools and technologies for life science research, is implementing a 1-for-10 reverse stock split. This move aims to strengthen the company's market position and ensure continued compliance with Nasdaq listing requirements.

Event Description On March 6, 2026, at a Special Meeting of Stockholders, Harvard Bioscience shareholders approved a proposal authorizing the Board of Directors to implement a reverse stock split within a specified ratio range. The Board has now set this ratio at 1-for-10.

This means that for every ten shares of Harvard Bioscience common stock you owned, you will now own one share. While the number of shares decreases, the price per share will proportionally increase. For example, if you owned 100 shares trading at $0.75 each (total value $75), after the 1-for-10 split, you would own 10 shares, each theoretically valued at approximately $7.50, maintaining your total investment value at $75 immediately after the split.

The company primarily undertakes this reverse stock split to regain and maintain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. Harvard Bioscience's stock has recently traded below this threshold, risking its Nasdaq listing. By consolidating shares and increasing the per-share price, the company aims to meet this crucial listing standard.

A higher stock price also improves the company's standing with institutional investors, who often avoid "penny stocks" or those trading below certain price points. This could broaden the company's investor base and enhance its market appeal.

Key Dates

• Shareholder Approval Date: March 6, 2026 (Special Meeting of Stockholders)
• Effective Date of Reverse Stock Split: 4:30 p.m. Eastern Time on March 13, 2026
• Commencement of Split-Adjusted Trading: Market open on March 16, 2026, on the Nasdaq Global Market

Impact Assessment

• Shareholders:
  • Share Count and Price: Your total number of shares will decrease by a factor of ten, and the price per share will increase proportionally. Your overall investment value should remain the same immediately after the split.
  • Fractional Shares: If you end up with a fractional share, the company's transfer agent will combine these fractions and sell them on the open market. You will then receive a cash payment for your fractional share's value, based on the common stock's closing price on the effective date.
• Holders of Equity Awards/Warrants: The company will proportionally adjust the number of shares underlying outstanding stock options, restricted stock units, and warrants, along with their exercise prices.
• Company's Nasdaq Listing Status: The company aims to regain and maintain compliance with Nasdaq's minimum bid price requirement, mitigating the risk of delisting.
• Company's Market Perception: A higher stock price may improve perception among institutional investors and potentially broaden the investor base.

Financial Impact The total authorized shares of common stock and the par value per share will both remain unchanged. However, the number of issued and outstanding common shares will decrease proportionally. The company expects its total market capitalization to remain the same immediately after the split, as the share price increase should offset the reduction in outstanding shares. The cash payment for fractional shares will lead to a minor cash outflow for the company.

Key Takeaways for Investors

• Underlying Business Performance: Investors should closely scrutinize Harvard Bioscience's future financial reports, focusing on revenue growth, profitability, and cash flow. The company's long-term success and stock price depend on its ability to execute its business strategy, innovate in the life science tools market, and deliver consistent financial results.
• Strategic Initiatives: Investors should look for concrete plans and progress updates on the specific strategies Harvard Bioscience implements to drive growth, improve operational efficiency, and enhance its competitive position.
• Risks: The stock price may not sustain its higher level post-split if underlying business fundamentals do not improve. The reverse split does not guarantee increased institutional investment or a sustained higher valuation. Continued market volatility and competitive pressures remain factors.
• What to Watch For Next: Investors should monitor the stock's trading performance after March 16, 2026, to see if the higher price is sustained and if the company successfully regains and maintains Nasdaq compliance. More importantly, investors should focus on Harvard Bioscience's upcoming earnings reports and any announcements regarding its operational performance and strategic direction. These will provide the true indicators of the company's health and future prospects.